Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gentium has announced the commencement of the phase 1 clinical study of defibrotide (DF) in healthy adults in Japan.
Subscribe to our email newsletter
The first subject of the study is administered with defibrotide by the medical team from National University Corporation Hamamatsu University School of Medicine (HSUM), Fukushima Medical University.
The study is designed to assess the safety and pharmacokinetic profile of Defibrotide in healthy adults.
Gentium is providing defibrotide in addition to technical support to HSUM.